Creo Medical Group (LON:CREO) Announces Quarterly Earnings Results

Creo Medical Group (LON:CREO) posted its quarterly earnings data on Wednesday. The company reported GBX (2) EPS for the quarter, Digital Look Earnings reports. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.

Creo Medical Group Price Performance

Shares of LON CREO traded down GBX 1.48 during midday trading on Wednesday, reaching GBX 10.40. 6,520,655 shares of the stock traded hands, compared to its average volume of 775,233. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19. The stock has a market capitalization of £50.52 million, a PE ratio of 10.40 and a beta of 1.56. Creo Medical Group has a one year low of GBX 9.52 and a one year high of GBX 18.50. The company’s 50 day moving average is GBX 12.77 and its 200 day moving average is GBX 12.87.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a research note on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.